reserpine has been researched along with bm 212 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alfonso, S; Battilocchio, C; Biava, M; Botta, M; Buroni, S; Canseco, JO; De Logu, A; De Rossi, E; Ioerger, TR; Javid, B; La Rosa, V; Manetti, F; Pasca, MR; Poce, G; Porretta, GC; Raju, RM; Rubin, EJ; Sacchettini, JC; Sorrentino, F | 1 |
1 other study(ies) available for reserpine and bm 212
Article | Year |
---|---|
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212.
Topics: Animals; Antitubercular Agents; Carbon Radioisotopes; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cattle; DNA Mutational Analysis; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Genomic Library; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Mycobacterium bovis; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Mycobacterium tuberculosis; Piperazines; Pyrroles; Reserpine; Verapamil | 2012 |